- Home
- STR vs OCUL Comparison
STR vs OCUL Comparison
Compare STR & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STR
- OCUL
- Stock Information
- Founded
- STR 2016
- OCUL 2006
- Country
- STR United States
- OCUL United States
- Employees
- STR N/A
- OCUL N/A
- Industry
- STR Oil & Gas Production
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- STR Energy
- OCUL Health Care
- Exchange
- STR Nasdaq
- OCUL Nasdaq
- Market Cap
- STR 1.7B
- OCUL 1.4B
- IPO Year
- STR N/A
- OCUL 2014
- Fundamental
- Price
- STR $21.86
- OCUL $8.09
- Analyst Decision
- STR Buy
- OCUL Strong Buy
- Analyst Count
- STR 6
- OCUL 8
- Target Price
- STR $29.60
- OCUL $16.50
- AVG Volume (30 Days)
- STR 790.0K
- OCUL 842.8K
- Earning Date
- STR 02-26-2025
- OCUL 03-10-2025
- Dividend Yield
- STR 6.83%
- OCUL N/A
- EPS Growth
- STR N/A
- OCUL N/A
- EPS
- STR N/A
- OCUL N/A
- Revenue
- STR $618,668,000.00
- OCUL $61,442,000.00
- Revenue This Year
- STR $6.44
- OCUL $11.40
- Revenue Next Year
- STR N/A
- OCUL $13.58
- P/E Ratio
- STR N/A
- OCUL N/A
- Revenue Growth
- STR 13.74
- OCUL 6.45
- 52 Week Low
- STR $18.40
- OCUL $3.92
- 52 Week High
- STR $25.95
- OCUL $11.78
- Technical
- Relative Strength Index (RSI)
- STR 60.52
- OCUL 40.09
- Support Level
- STR $21.56
- OCUL $7.99
- Resistance Level
- STR $22.18
- OCUL $8.43
- Average True Range (ATR)
- STR 0.52
- OCUL 0.38
- MACD
- STR 0.37
- OCUL -0.02
- Stochastic Oscillator
- STR 91.02
- OCUL 25.90
About STR Sitio Royalties Corp.
Sitio Royalties Corp is a pure-play mineral and royalty company. The group focuses on investing in mineral and royalty interests in the Permian and other productive U.S. oil basins.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.